Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-α

Terrence Metz, Tasima Haque, Hongmei Chen, Satya Prakash, Devendra Amre, Sujata Das

Research output: Contribution to journalArticle

Abstract

Recent studies have implicated the cytokine tumor necrosis factor-alpha (TNF-α) in the inflammation associated with Crohn's disease (CD). Thalidomide has been shown to decrease this inflammation by the suppression of TNF-α secretion. However, side effects associated with thalidomide have precluded its widespread usage. In the present study we investigated the efficacy of a "targeted delivery approach" for thalidomide at the site of inflammation. We observed that alginate-poly-l-lysine-alginate (APA) polymer-based microcapsule formulations that encapsulate thalidomide could be designed. These capsules could be delivered at target sites where they almost entirely suppress TNF-α secretion in lipopolysaccharide activated RAW 264.7 macrophage cells in vitro. These findings indicate that targeted delivery of thalidomide using APA capsules could facilitate its usage in reducing the inflammation associated with chronic conditions such as Crohn's disease and ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)331-337
Number of pages7
JournalDrug Delivery
Volume13
Issue number5
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Thalidomide
Capsules
Tumor Necrosis Factor-alpha
Inflammation
Crohn Disease
Lysine
Ulcerative Colitis
Lipopolysaccharides
Polymers
Macrophages
In Vitro Techniques
Cytokines
alginic acid

Keywords

  • Alginate
  • Artificial Cells
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Microcapsule
  • Polylysine
  • Thalidomide
  • TNF-α

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-α. / Metz, Terrence; Haque, Tasima; Chen, Hongmei; Prakash, Satya; Amre, Devendra; Das, Sujata.

In: Drug Delivery, Vol. 13, No. 5, 01.10.2006, p. 331-337.

Research output: Contribution to journalArticle

Metz, Terrence ; Haque, Tasima ; Chen, Hongmei ; Prakash, Satya ; Amre, Devendra ; Das, Sujata. / Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-α. In: Drug Delivery. 2006 ; Vol. 13, No. 5. pp. 331-337.
@article{f47247afcced4287b9e7fddc22e1286b,
title = "Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-α",
abstract = "Recent studies have implicated the cytokine tumor necrosis factor-alpha (TNF-α) in the inflammation associated with Crohn's disease (CD). Thalidomide has been shown to decrease this inflammation by the suppression of TNF-α secretion. However, side effects associated with thalidomide have precluded its widespread usage. In the present study we investigated the efficacy of a {"}targeted delivery approach{"} for thalidomide at the site of inflammation. We observed that alginate-poly-l-lysine-alginate (APA) polymer-based microcapsule formulations that encapsulate thalidomide could be designed. These capsules could be delivered at target sites where they almost entirely suppress TNF-α secretion in lipopolysaccharide activated RAW 264.7 macrophage cells in vitro. These findings indicate that targeted delivery of thalidomide using APA capsules could facilitate its usage in reducing the inflammation associated with chronic conditions such as Crohn's disease and ulcerative colitis.",
keywords = "Alginate, Artificial Cells, Crohn's Disease, Inflammatory Bowel Disease, Microcapsule, Polylysine, Thalidomide, TNF-α",
author = "Terrence Metz and Tasima Haque and Hongmei Chen and Satya Prakash and Devendra Amre and Sujata Das",
year = "2006",
month = "10",
day = "1",
doi = "10.1080/10717540500466097",
language = "English (US)",
volume = "13",
pages = "331--337",
journal = "Drug Delivery",
issn = "1071-7544",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-α

AU - Metz, Terrence

AU - Haque, Tasima

AU - Chen, Hongmei

AU - Prakash, Satya

AU - Amre, Devendra

AU - Das, Sujata

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Recent studies have implicated the cytokine tumor necrosis factor-alpha (TNF-α) in the inflammation associated with Crohn's disease (CD). Thalidomide has been shown to decrease this inflammation by the suppression of TNF-α secretion. However, side effects associated with thalidomide have precluded its widespread usage. In the present study we investigated the efficacy of a "targeted delivery approach" for thalidomide at the site of inflammation. We observed that alginate-poly-l-lysine-alginate (APA) polymer-based microcapsule formulations that encapsulate thalidomide could be designed. These capsules could be delivered at target sites where they almost entirely suppress TNF-α secretion in lipopolysaccharide activated RAW 264.7 macrophage cells in vitro. These findings indicate that targeted delivery of thalidomide using APA capsules could facilitate its usage in reducing the inflammation associated with chronic conditions such as Crohn's disease and ulcerative colitis.

AB - Recent studies have implicated the cytokine tumor necrosis factor-alpha (TNF-α) in the inflammation associated with Crohn's disease (CD). Thalidomide has been shown to decrease this inflammation by the suppression of TNF-α secretion. However, side effects associated with thalidomide have precluded its widespread usage. In the present study we investigated the efficacy of a "targeted delivery approach" for thalidomide at the site of inflammation. We observed that alginate-poly-l-lysine-alginate (APA) polymer-based microcapsule formulations that encapsulate thalidomide could be designed. These capsules could be delivered at target sites where they almost entirely suppress TNF-α secretion in lipopolysaccharide activated RAW 264.7 macrophage cells in vitro. These findings indicate that targeted delivery of thalidomide using APA capsules could facilitate its usage in reducing the inflammation associated with chronic conditions such as Crohn's disease and ulcerative colitis.

KW - Alginate

KW - Artificial Cells

KW - Crohn's Disease

KW - Inflammatory Bowel Disease

KW - Microcapsule

KW - Polylysine

KW - Thalidomide

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=33746824216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746824216&partnerID=8YFLogxK

U2 - 10.1080/10717540500466097

DO - 10.1080/10717540500466097

M3 - Article

C2 - 16877307

AN - SCOPUS:33746824216

VL - 13

SP - 331

EP - 337

JO - Drug Delivery

JF - Drug Delivery

SN - 1071-7544

IS - 5

ER -